In patients with ovarian and breast cancer receiving platinum‐based adjuvant chemotherapy, patients lacking BRCA locus‐specific LOH had significantly worse OS than those with BRCA2 homozygous deletion.27, 28. This evidence concerns the gene BRCA2 and breast cancer.